@article {7949,
	title = {Four cycles of paclitaxel and carboplatin as adjuvant treatment in early-stage ovarian cancer: A six-year experience of the Hellenic Cooperative Oncology Group},
	journal = {BMC Cancer},
	volume = {6},
	year = {2006},
	note = {Cited By :7Export Date: 21 February 2017},
	month = {2006},
	abstract = {Background: Surgery can cure a significant percentage of ovarian carcinoma confined to the pelvis. Nevertheless, there is still a 10-50\% recurrence rate. We administered paclitaxel/carboplatin as adjuvant treatment in early-stage ovarian carcinoma. Methods: Patients with stages Ia or Ib, Grade 2 or 3 and Ic to IIb (any grade) were included. Patients were treated with 4 cycles of Paclitaxel 175 mg/m2 and Carboplatin [area under the curve (AUC) 6 (Calvert Formula)] every 3 weeks. Results: Sixty-nine patients with no residual disease following cytoreductive surgery and minimal or modified surgical staging were included in this analysis. Grade 3 or 4 neutropenia occured in 29.9\% of patients, while neutropenic fever was reported in 4.5\%. Neurotoxicity (all Grade 1 or 2) was reported in 50\% of cases. Median follow-up was 62 months. 5-year overall survival (OS) and relapse-free survival (RFS) were: 87\% (95\% confidence intervals [CI]: 78-96) and 79\% (95\% CI: 69-89), respectively. Significantly fewer patients with stages Ic-IIb and tumor grade 2 or 3 achieved a 5-year RFS than patients with only one of these two factors (73\% vs 92\%, p = 0.03). Conclusion: Paclitaxel/Carboplatin chemotherapy is a safe and effective adjuvant treatment in early-stage ovarian carcinoma Patients with stages Ic-IIb and tumor grade 2 or 3 may benefit from more extensive treatment. {\textcopyright} 2006 Bamias et al; licensee BioMed Central Ltd.},
	url = {https://www.scopus.com/inward/record.uri?eid=2-s2.0-33749634598\&doi=10.1186\%2f1471-2407-6-228\&partnerID=40\&md5=2f9c887eb4644eeff26093a3a2a077ae},
	author = {Bamias, A. and Papadimitriou, C. and Efstathiou, E. and Rodolakis, A. and Vlahos, G. and Voulgaris, Z. and Bozas, G. and Fountzilas, G. and Aravantinos, G. and Razis, E. and Gika, D. and Dimopoulos, M.A.}
}
